查看購物車
  • Simplified Chinese
  • English
  • Japanese
2021 - 2031 年抗肥胖藥物市場規模及預測、全球及地區佔有率、趨勢及成長機會分析報告，涵蓋：按類型、藥物類別、應用、給藥途徑、配銷通路和地理分類
市場調查報告書
商品編碼
1761154

2021 - 2031 年抗肥胖藥物市場規模及預測、全球及地區佔有率、趨勢及成長機會分析報告，涵蓋：按類型、藥物類別、應用、給藥途徑、配銷通路和地理分類

Anti-obesity Drugs Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Drug Class, Application, Route of Administration, and Distribution Channel, and Geography
出版日期: | 出版商: The Insight Partners | 英文 316 Pages | 訂單完成後即時交付

價格

根據我們最新的研究報告《2031年抗肥胖藥物市場預測－全球分析－按類型、藥物類別、給藥途徑、應用、配銷通路和地理分類》，預計該市場規模將從2024年的158.5億美元成長到2031年的1772.7億美元；預計2025-20億美元成長到2031年的1772.7億美元；預計2025-2031年期間的複合年成長率為3%。肥胖症的日益普及以及人們對體重管理解決方案的認知和需求的不斷提高，正在推動抗肥胖藥物市場規模的不斷成長。然而，副作用和安全問題阻礙了抗肥胖藥物市場的成長。此外，精準醫療和個人化抗肥胖藥物治療方案預計將在未來幾年帶來新的抗肥胖藥物市場趨勢。

就收入而言，北美在 2024 年佔據市場主導地位。據估計，在預測期內，它將佔據全球市場的主導地位。美國是世界上最大的抗肥胖藥物市場。與糖尿病相關的慢性傷口包括足部、靜脈和壓瘡。根據《國際組織修復與再生期刊》，1% 的美國人口患有活動性或癒合的靜脈潰瘍。根據美國疾病管制與預防中心 (CDC) 發布的《2020 年國家糖尿病統計報告》，美國各年齡層有 3,420 萬人患有糖尿病，每年約有 100 萬名糖尿病患者患有足部潰瘍，而 600-700 萬名糖尿病患者一生中會患潰瘍。因此，糖尿病和慢性傷口發生率的上升導致傷口敷料的需求增加，並有助於預測期內抗肥胖藥物市場的成長。美國公司專注於透過採用有機和無機策略來擴大其影響力。 2021年10月，Medline Industries宣布投資7,750萬美元在堪薩斯州建設新的配送中心。

減肥藥市場分析

新興經濟體擴張為未來提供市場機會

根據 2023 年 7 月發表的《柳葉刀》研究，預計到 2050 年，印度將有約 4.5 億個成年人超重或肥胖。 2021 年，全球被歸類為超重或肥胖的成年人中有一半以上生活在印度，有 1.8 億人受到影響；中國有 4.02 億人；巴西有 8800 萬人；俄羅斯有 7,100 萬人；墨西哥有 5,800 萬人；印尼有 5,200 萬人；埃及有 4100 萬人；

根據世界肥胖聯合會的數據，越南、印尼和孟加拉的肥胖盛行率正在上升，近幾十年來成長率達到6-9%。由於城市化、久坐不動的生活方式和飲食習慣的變化，新興國家的肥胖盛行率不斷上升，這增加了對抗肥胖藥物的需求。很大一部分人口仍未得到診斷或治療，這為製藥公司提供了一個尚未完全滲透的市場，使其有機會推出新的療法並擴大其覆蓋範圍。禮來公司正準備在2026年之前在印度、巴西和墨西哥推出其減肥和糖尿病藥物tirzepatide（糖尿病藥物Mounjaro和肥胖藥物Zepbound）。

巴西正在加強醫療基礎設施和肥胖管理項目，為新型抗肥胖藥物的引進和報銷創造有利環境。 2024年4月，巴西在聖保羅州奧托蘭迪亞開設了一家實驗室，專門生產糖尿病和肥胖症藥物，其中包括Ozempic的活性成分利拉魯肽。這家由EMS營運的工廠也將生產Ozempic的關鍵成分索馬魯肽，該成分的專利有效期至2026年3月，目前正接受巴西國家衛生監督局（ANVISA）的審查。該工廠投資6,000萬巴西雷亞爾（約1,093萬美元），是巴西首個此類工廠，將支持聯邦政府的「健康經濟產業綜合體」計畫。

根據世界經濟論壇的數據，初期獲取抗肥胖藥物的管道可能僅限於私人市場和自付費用。不過，未來中等收入國家的保險保障和學名藥的出現，或許能提高這些藥物的可及性。因此，不斷上升的肥胖率、政府的支持性舉措以及產品創新預計將為新興國家的市場創造未來的成長機會。

抗肥胖藥物市場報告細分分析

有助於得出抗肥胖藥物市場分析的關鍵部分是類型、藥物類別、給藥途徑、應用和配銷通路。

根據類型，減肥藥市場分為處方藥和非處方藥。 2024年，處方藥市場佔有相對較大佔有率。

依藥物類別，減肥藥市場細分為GLP-1激動劑、脂肪酶抑制劑、MC4R激動劑等。 GLP-1激動劑在2024年佔據了最大的市場佔有率。 GLP-1激動劑細分市場進一步細分為司美格魯肽、利拉魯肽和替澤帕肽。

根據應用，減肥藥市場可分為抑制食慾、抑制脂肪吸收/消化酵素、促進代謝、合併用藥。 2024年，抑制食慾類藥物佔據了最大的市場。

就給藥途徑而言，減肥藥市場分為口服和注射兩種。 2024年，口服藥物佔據市場主導地位。

根據配銷通路，減肥藥市場可分為醫院藥房、線上通路和零售藥房。 2024年，醫院藥局佔據了市場主導地位。

抗肥胖藥物市場：競爭格局與關鍵發展

Novo Nordisk AS、Eli Lilly and Co、GSK Plc、Rhythm Pharmaceuticals Inc、Currax Pharmaceuticals LLC.、VIVUS LLC、AdvaCare Pharma USA LL、Teva Pharmaceutical Industries Ltd、Sun Pharmaceutical Industries Ltd 和 F. Hoffmann-La Roche Ltd 是抗肥胖藥物市場的主要公司。

世界衛生組織、世界肥胖地圖集、美國食品藥物管理局、柳葉刀雜誌、世界肥胖聯合會、世界經濟論壇、疾病管制與預防中心 (CDC)、國際糖尿病聯盟 (IDF)、經濟合作暨發展組織 (OECD) 是編寫抗肥胖藥物市場報告時參考的主要和次要來源。

目錄

第1章：簡介

第2章：執行摘要

  • 分析師市場展望

第3章：研究方法

  • 二次研究
  • 初步研究
    • 假設表述：
    • 宏觀經濟因素分析：
    • 顯影基數：
    • 數據三角測量：
    • 國家級資料：
  • 假設和局限性

第4章：抗肥胖藥物市場格局

  • 概述
  • PEST分析

第5章：抗肥胖藥物市場－關鍵市場動態

  • 抗肥胖藥物市場－關鍵市場動態
  • 市場促進因素
    • 肥胖症日益普遍
    • 人們對體重管理解決方案的認知和需求不斷提高
  • 市場限制
    • 副作用和安全問題
  • 市場機會
    • 新興經濟體的擴張
  • 未來趨勢
    • 精準醫療和個人化抗肥胖藥物治療方案
  • 促進因素和限制因素的影響：

第6章：抗肥胖藥物市場－全球市場分析

  • 2021-2031年抗肥胖藥物市場收入
  • 抗肥胖藥物市場預測分析

第7章：抗肥胖藥物市場分析－依類型

  • 處方藥
  • 非處方藥

第 8 章：抗肥胖藥物市場分析 - 按藥物類別

  • GLP-1激動劑
  • 脂肪酶抑制劑
  • MC4R激動劑
  • 其他

第9章：抗肥胖藥物市場分析－依應用

  • 抑制食慾
  • 抑制脂肪吸收或消化酶
  • 代謝增強
  • 組合

第 10 章：抗肥胖藥物市場分析 - 按給藥途徑

  • 口服
  • 腸外

第 11 章：抗肥胖藥物市場分析 - 按配銷通路

  • 醫院藥房
  • 線上通路
  • 零售藥局

第 12 章：抗肥胖藥物市場 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第13章：產業格局

  • 概述
  • 新產品開發/核准
  • 其他商業策略

第 14 章：公司簡介

  • Novo Nordisk AS
  • Eli Lilly and Co
  • GSK Plc
  • Rhythm Pharmaceuticals Inc
  • Currax Pharmaceuticals LLC.
  • VIVUS LLC
  • AdvaCare Pharma USA LLC
  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd
  • F. Hoffmann-La Roche Ltd

第 15 章：附錄

Product Code: TIPRE00006850

According to our new research study on "Anti-obesity Drugs Market Forecast to 2031 -Global Analysis - by Type, Drug Class, Route of Administration, Application, Distribution Channel, and Geography," the market is anticipated to grow from US$ 15.85 billion in 2024 and is projected to reach US$ 177.27 billion by 2031; it is expected to register a CAGR of 35.3% during 2025-2031. Mounting prevalence of obesity and increased awareness and demand for weight management solutions are contributing to the growing anti-obesity drugs market size. However, the side effects and safety concerns hamper the anti-obesity drugs market growth. Further, precision medicine and personalized anti-obesity drug regimens is expected to bring in new anti-obesity drugs market trends in the coming years.

In terms of revenue, North America dominated the market in 2024. It is estimated to dominate the global market during the forecast period. The US is the largest market for anti-obesity drugs in the world. Chronic wounds associated with diabetes include foot, venous, and pressure ulcers. According to The International Journal of Tissue Repair and Regeneration, active or healed venous ulcers occur in 1% of the US population. As per the National Diabetes Statistics Report 2020, a publication of the Centers for Disease Control and Prevention (CDC), 34.2 million people of all ages in the US have diabetes, and ~1 million diabetics develop a foot ulcer each year, while 6-7 million diabetes patients develop ulcers in their lifetime. Thus, the rising incidence of diabetes and chronic wounds leads to an increase in demand for wound dressing and contributes to the anti-obesity drugs market growth during the forecast period. Companies in the US are focused on expanding their presence by adopting organic and inorganic strategies. In October 2021, Medline Industries announced an investment of US$ 77.5 million to build a new distribution center in Kansas.

Anti-obesity Drugs Market Analysis

Expansion in Emerging Economies to Provide Market Opportunities in Future

According to a Lancet study published in July 2023, approximately 450 million adults in India are expected to be overweight or obese by 2050. In 2021, more than half of the world's adults who were classified as overweight or obese lived in India, with 180 million affected individuals; China, with 402 million; Brazil, with 88 million; Russia, with 71 million; Mexico, with 58 million; Indonesia, with 52 million; and Egypt, with 41 million.

According to the World Obesity Federation, Vietnam, Indonesia, and Bangladesh are experiencing rising obesity prevalence, with a rate of 6-9% in recent decades. The mounting prevalence of obesity in emerging countries due to urbanization, sedentary lifestyles, and dietary changes has increased the demand for anti-obesity drugs. A large segment of the population remains undiagnosed or untreated, offering an underpenetrated market for pharmaceutical companies to introduce new therapies and expand their reach. Eli Lilly is preparing to launch its weight-loss and diabetes drug, tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity), in India, Brazil, and Mexico by 2026.

Brazil is enhancing healthcare infrastructure and obesity management programs, fostering a supportive environment for the introduction and reimbursement of new anti-obesity medications. In April 2024, Brazil opened a laboratory in Hortolandia, Sao Paulo State, dedicated to producing medications for diabetes and obesity, including liraglutide, an active ingredient found in Ozempic. The EMS-operated plant will also produce semaglutide, a key ingredient in Ozempic, which has a patent valid until March 2026 and is already under review by Agencia Nacional de Vigilancia Sanitaria (ANVISA). With an investment of R$60 million (~US$ 10.93 million), this facility is the first of its kind in Brazil and supports the federal government's Health Economic-Industrial Complex initiatives.

According to the World Economic Forum, initial access to anti-obesity medications may be limited to private markets and out-of-pocket payments. Still, future insurance coverage and generic versions in middle-income countries could improve the accessibility of these medications. Thus, the rising obesity rates, supportive government initiatives, and product innovations are expected to create future growth opportunities for the market in emerging countries.

Anti-obesity Drugs Market Report Segmentation Analysis

Key segments that contributed to the derivation of the anti-obesity drugs market analysis are type, drug class, route of administration, application, and distribution channel.

Based on type, the anti-obesity drugs market is bifurcated into prescription and OTC. The prescription segment held relatively larger share of the market in 2024.

By drug class, the anti-obesity drugs market is segmented into GLP-1 agonists, lipase inhibitors, MC4R agonists, and others. The GLP-1 Agonist segment held the largest share of the market in 2024. GLP-1 agonists segment further subsegmented into Semaglutide, Liraglutide, Tirzepatide.

Based on application, the anti-obesity drugs market is categorized into appetite suppression, inhibition of fat absorption/digestive enzymes, metabolic enhancement, and combination. The appetite suppression segment held a largest share of the market in 2024.

In terms of route of administration, the anti-obesity drugs market is bifurcated into oral and parenteral. The oral segment dominated the market in 2024.

Per distribution channel, the anti-obesity drugs market is categorized into hospital pharmacies, online channel, and retail pharmacies. The hospital pharmacies segment dominated the market in 2024.

Anti-obesity Drugs Market: Competitive Landscape and Key Developments

Novo Nordisk AS, Eli Lilly and Co, GSK Plc, Rhythm Pharmaceuticals Inc, Currax Pharmaceuticals LLC., VIVUS LLC, AdvaCare Pharma USA LL, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, and F. Hoffmann-La Roche Ltd are among the key companies operating in the anti-obesity drugs market.

The World Health Organization, World Obesity Atlas, The U.S. Food and Drug Administration, The Lancet Journal, World Obesity Federation, World Economic Forum, Centers for Disease Control and Prevention (CDC), the International Diabetes Federation (IDF), the Organization for Economic Co-operation and Development (OECD) are primary and secondary sources referred to while preparing the anti-obesity drugs market report.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Analyst Market Outlook

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:
  • 3.3 Assumptions and Limitations

4. Anti-Obesity Drugs Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Anti-Obesity Drugs Market - Key Market Dynamics

  • 5.1 Anti-Obesity Drugs Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Mounting Prevalence of Obesity
    • 5.2.2 Increased Awareness and Demand for Weight Management Solutions
  • 5.3 Market Restraints
    • 5.3.1 Side Effects and Safety Concerns
  • 5.4 Market Opportunities
    • 5.4.1 Expansion in Emerging Economies
  • 5.5 Future Trends
    • 5.5.1 Precision Medicine and Personalized Anti-Obesity Drug Regimens
  • 5.6 Impact of Drivers and Restraints:

6. Anti-Obesity Drugs Market - Global Market Analysis

  • 6.1 Anti-Obesity Drugs Market Revenue (US$ Million), 2021-2031
  • 6.2 Anti-Obesity Drugs Market Forecast Analysis

7. Anti-Obesity Drugs Market Analysis - by Type

  • 7.1 Prescription Drugs
    • 7.1.1 Overview
    • 7.1.2 Prescription Drugs: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 OTC Drugs
    • 7.2.1 Overview
    • 7.2.2 OTC Drugs: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)

8. Anti-Obesity Drugs Market Analysis - by Drug Class

  • 8.1 GLP-1 Agonist
    • 8.1.1 Overview
    • 8.1.2 GLP-1 Agonist: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Lipase Inhibitors
    • 8.2.1 Overview
    • 8.2.2 Lipase Inhibitors: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 MC4R agonist
    • 8.3.1 Overview
    • 8.3.2 MC4R agonist: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)

9. Anti-Obesity Drugs Market Analysis - by Application

  • 9.1 Appetite Suppression
    • 9.1.1 Overview
    • 9.1.2 Appetite Suppression: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Inhibition of Fat Absorption or Digestive Enzymes
    • 9.2.1 Overview
    • 9.2.2 Inhibition of Fat Absorption or Digestive Enzymes: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Metabolic Enhancement
    • 9.3.1 Overview
    • 9.3.2 Metabolic Enhancement: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Combination
    • 9.4.1 Overview
    • 9.4.2 Combination: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)

10. Anti-Obesity Drugs Market Analysis - by Route Of Administration

  • 10.1 Oral
    • 10.1.1 Overview
    • 10.1.2 Oral: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Parenteral
    • 10.2.1 Overview
    • 10.2.2 Parenteral: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)

11. Anti-Obesity Drugs Market Analysis - by Distribution Channel

  • 11.1 Hospital Pharmacies
    • 11.1.1 Overview
    • 11.1.2 Hospital Pharmacies: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.2 Online Channel
    • 11.2.1 Overview
    • 11.2.2 Online Channel: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.3 Retail Pharmacies
    • 11.3.1 Overview
    • 11.3.2 Retail Pharmacies: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)

12. Anti-Obesity Drugs Market - Geographical Analysis

  • 12.1 Overview
  • 12.2 North America
    • 12.2.1 North America Anti-Obesity Drugs Market Overview
    • 12.2.2 North America: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
    • 12.2.3 North America: Anti-Obesity Drugs Market Breakdown, by Type
      • 12.2.3.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
    • 12.2.4 North America: Anti-Obesity Drugs Market Breakdown, by Drug Class
      • 12.2.4.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 12.2.4.1.1 North America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    • 12.2.5 North America: Anti-Obesity Drugs Market Breakdown, by Application
      • 12.2.5.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
    • 12.2.6 North America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
      • 12.2.6.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
    • 12.2.7 North America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.2.7.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
    • 12.2.8 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.2.8.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.2.8.2 United States: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.2.8.2.1 United States: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.2.8.2.2 United States: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.2.8.2.2.1 United States: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.2.8.2.3 United States: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.2.8.2.4 United States: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.2.8.2.5 United States: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.2.8.3 Canada: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.2.8.3.1 Canada: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.2.8.3.2 Canada: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.2.8.3.2.1 Canada: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.2.8.3.3 Canada: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.2.8.3.4 Canada: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.2.8.3.5 Canada: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.2.8.4 Mexico: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.2.8.4.1 Mexico: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.2.8.4.2 Mexico: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.2.8.4.2.1 Mexico: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.2.8.4.3 Mexico: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.2.8.4.4 Mexico: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.2.8.4.5 Mexico: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  • 12.3 Europe
    • 12.3.1 Europe Anti-Obesity Drugs Market Overview
    • 12.3.2 Europe: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
    • 12.3.3 Europe: Anti-Obesity Drugs Market Breakdown, by Type
      • 12.3.3.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
    • 12.3.4 Europe: Anti-Obesity Drugs Market Breakdown, by Drug Class
      • 12.3.4.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 12.3.4.1.1 Europe: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    • 12.3.5 Europe: Anti-Obesity Drugs Market Breakdown, by Application
      • 12.3.5.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
    • 12.3.6 Europe: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
      • 12.3.6.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
    • 12.3.7 Europe: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.3.7.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
    • 12.3.8 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.3.8.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.3.8.2 Germany: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.3.8.2.1 Germany: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.3.8.2.2 Germany: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.3.8.2.2.1 Germany: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.3.8.2.3 Germany: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.3.8.2.4 Germany: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.3.8.2.5 Germany: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.3.8.3 United Kingdom: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.3.8.3.1 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.3.8.3.2 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.3.8.3.2.1 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.3.8.3.3 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.3.8.3.4 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.3.8.3.5 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.3.8.4 France: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.3.8.4.1 France: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.3.8.4.2 France: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.3.8.4.2.1 France: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.3.8.4.3 France: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.3.8.4.4 France: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.3.8.4.5 France: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.3.8.5 Spain: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.3.8.5.1 Spain: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.3.8.5.2 Spain: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.3.8.5.2.1 Spain: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.3.8.5.3 Spain: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.3.8.5.4 Spain: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.3.8.5.5 Spain: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.3.8.6 Italy: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.3.8.6.1 Italy: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.3.8.6.2 Italy: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.3.8.6.2.1 Italy: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.3.8.6.3 Italy: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.3.8.6.4 Italy: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.3.8.6.5 Italy: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.3.8.7 Rest of Europe: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.3.8.7.1 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.3.8.7.2 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.3.8.7.2.1 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.3.8.7.3 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.3.8.7.4 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.3.8.7.5 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  • 12.4 Asia Pacific
    • 12.4.1 Asia Pacific Anti-Obesity Drugs Market Overview
    • 12.4.2 Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
    • 12.4.3 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Type
      • 12.4.3.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
    • 12.4.4 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Drug Class
      • 12.4.4.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 12.4.4.1.1 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    • 12.4.5 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Application
      • 12.4.5.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
    • 12.4.6 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
      • 12.4.6.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
    • 12.4.7 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.4.7.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
    • 12.4.8 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.4.8.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.4.8.2 China: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.4.8.2.1 China: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.4.8.2.2 China: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.4.8.2.2.1 China: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.4.8.2.3 China: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.4.8.2.4 China: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.4.8.2.5 China: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.4.8.3 Japan: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.4.8.3.1 Japan: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.4.8.3.2 Japan: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.4.8.3.2.1 Japan: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.4.8.3.3 Japan: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.4.8.3.4 Japan: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.4.8.3.5 Japan: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.4.8.4 India: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.4.8.4.1 India: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.4.8.4.2 India: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.4.8.4.2.1 India: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.4.8.4.3 India: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.4.8.4.4 India: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.4.8.4.5 India: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.4.8.5 Australia: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.4.8.5.1 Australia: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.4.8.5.2 Australia: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.4.8.5.2.1 Australia: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.4.8.5.3 Australia: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.4.8.5.4 Australia: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.4.8.5.5 Australia: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.4.8.6 South Korea: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.4.8.6.1 South Korea: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.4.8.6.2 South Korea: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.4.8.6.2.1 South Korea: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.4.8.6.3 South Korea: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.4.8.6.4 South Korea: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.4.8.6.5 South Korea: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.4.8.7 Rest of APAC: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.4.8.7.1 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.4.8.7.2 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.4.8.7.2.1 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.4.8.7.3 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.4.8.7.4 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.4.8.7.5 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  • 12.5 Middle East and Africa
    • 12.5.1 Middle East and Africa Anti-Obesity Drugs Market Overview
    • 12.5.2 Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
    • 12.5.3 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Type
      • 12.5.3.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
    • 12.5.4 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class
      • 12.5.4.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 12.5.4.1.1 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    • 12.5.5 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Application
      • 12.5.5.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
    • 12.5.6 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
      • 12.5.6.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
    • 12.5.7 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.5.7.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
    • 12.5.8 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.5.8.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.5.8.2 Saudi Arabia: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.5.8.2.1 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.5.8.2.2 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.5.8.2.2.1 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.5.8.2.3 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.5.8.2.4 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.5.8.2.5 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.5.8.3 South Africa: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.5.8.3.1 South Africa: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.5.8.3.2 South Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.5.8.3.2.1 South Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.5.8.3.3 South Africa: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.5.8.3.4 South Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.5.8.3.5 South Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.5.8.4 United Arab Emirates: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.5.8.4.1 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.5.8.4.2 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.5.8.4.2.1 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.5.8.4.3 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.5.8.4.4 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.5.8.4.5 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.5.8.5 Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.5.8.5.1 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.5.8.5.2 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.5.8.5.2.1 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.5.8.5.3 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.5.8.5.4 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.5.8.5.5 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  • 12.6 South and Central America
    • 12.6.1 South and Central America Anti-Obesity Drugs Market Overview
    • 12.6.2 South and Central America: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
    • 12.6.3 South and Central America: Anti-Obesity Drugs Market Breakdown, by Type
      • 12.6.3.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
    • 12.6.4 South and Central America: Anti-Obesity Drugs Market Breakdown, by Drug Class
      • 12.6.4.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 12.6.4.1.1 South and Central America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    • 12.6.5 South and Central America: Anti-Obesity Drugs Market Breakdown, by Application
      • 12.6.5.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
    • 12.6.6 South and Central America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
      • 12.6.6.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
    • 12.6.7 South and Central America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.6.7.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
    • 12.6.8 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.6.8.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.6.8.2 Brazil: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.6.8.2.1 Brazil: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.6.8.2.2 Brazil: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.6.8.2.2.1 Brazil: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.6.8.2.3 Brazil: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.6.8.2.4 Brazil: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.6.8.2.5 Brazil: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.6.8.3 Argentina: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.6.8.3.1 Argentina: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.6.8.3.2 Argentina: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.6.8.3.2.1 Argentina: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.6.8.3.3 Argentina: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.6.8.3.4 Argentina: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.6.8.3.5 Argentina: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.6.8.4 Rest of South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.6.8.4.1 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.6.8.4.2 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.6.8.4.2.1 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.6.8.4.3 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.6.8.4.4 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.6.8.4.5 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

13. Industry Landscape

  • 13.1 Overview
  • 13.2 New Product Development/Approval
  • 13.3 Other Business Strategies

14. Company Profiles

  • 14.1 Novo Nordisk AS
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
  • 14.2 Eli Lilly and Co
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 GSK Plc
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
  • 14.4 Rhythm Pharmaceuticals Inc
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 Currax Pharmaceuticals LLC.
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 VIVUS LLC
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 AdvaCare Pharma USA LLC
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
  • 14.8 Teva Pharmaceutical Industries Ltd
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
  • 14.9 Sun Pharmaceutical Industries Ltd
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments
  • 14.10 F. Hoffmann-La Roche Ltd
    • 14.10.1 Key Facts
    • 14.10.2 Business Description
    • 14.10.3 Products and Services
    • 14.10.4 Financial Overview
    • 14.10.5 SWOT Analysis

15. Appendix

  • 15.1 About The Insight Partners
  • 15.2 Glossary of Terms

List Of Tables

  • Table 1. Anti-Obesity Drugs Market Segmentation
  • Table 2. Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million)
  • Table 3. Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million)
  • Table 4. Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 5. Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 6. Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 7. Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 8. Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 9. Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 10. Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 11. Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 12. Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 13. Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 14. Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 15. Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 16. North America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 17. North America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 18. North America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 19. North America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 20. North America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 21. North America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 22. North America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 23. North America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 24. North America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 25. North America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 26. North America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 27. North America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 28. North America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Country
  • Table 29. North America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Country
  • Table 30. United States: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 31. United States: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 32. United States: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 33. United States: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 34. United States: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 35. United States: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 36. United States: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 37. United States: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 38. United States: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 39. United States: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 40. United States: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 41. United States: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 42. Canada: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 43. Canada: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 44. Canada: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 45. Canada: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 46. Canada: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 47. Canada: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 48. Canada: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 49. Canada: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 50. Canada: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 51. Canada: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 52. Canada: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 53. Canada: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 54. Mexico: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 55. Mexico: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 56. Mexico: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 57. Mexico: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 58. Mexico: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 59. Mexico: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 60. Mexico: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 61. Mexico: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 62. Mexico: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 63. Mexico: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 64. Mexico: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 65. Mexico: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 66. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 67. Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 68. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 69. Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 70. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 71. Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 72. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 73. Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 74. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 75. Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 76. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 77. Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 78. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Country
  • Table 79. Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Country
  • Table 80. ADULT OBESITY IN 2030
  • Table 81. CHILD OBESITY IN 2030
  • Table 82. Germany: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 83. Germany: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 84. Germany: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 85. Germany: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 86. Germany: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 87. Germany: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 88. Germany: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 89. Germany: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 90. Germany: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 91. Germany: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 92. Germany: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 93. Germany: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 94. United Kingdom: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 95. United Kingdom: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 96. United Kingdom: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 97. United Kingdom: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 98. United Kingdom: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 99. United Kingdom: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 100. United Kingdom: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 101. United Kingdom: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 102. United Kingdom: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 103. United Kingdom: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 104. United Kingdom: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 105. United Kingdom: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 106. France: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 107. France: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 108. France: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 109. France: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 110. France: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 111. France: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 112. France: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 113. France: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 114. France: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 115. France: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 116. France: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 117. France: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 118. ADULT OBESITY IN 2030
  • Table 119. CHILD OBESITY IN 2030
  • Table 120. Spain: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 121. Spain: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 122. Spain: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 123. Spain: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 124. Spain: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 125. Spain: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 126. Spain: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 127. Spain: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 128. Spain: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 129. Spain: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 130. Spain: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 131. Spain: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 132. Italy: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 133. Italy: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 134. Italy: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 135. Italy: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 136. Italy: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 137. Italy: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 138. Italy: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 139. Italy: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 140. Italy: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 141. Italy: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 142. Italy: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 143. Italy: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 144. Rest of Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 145. Rest of Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 146. Rest of Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 147. Rest of Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 148. Rest of Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 149. Rest of Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 150. Rest of Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 151. Rest of Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 152. Rest of Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 153. Rest of Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 154. Rest of Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 155. Rest of Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 156. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 157. Asia Pacific: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 158. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 159. Asia Pacific: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 160. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 161. Asia Pacific: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 162. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 163. Asia Pacific: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 164. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 165. Asia Pacific: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 166. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 167. Asia Pacific: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 168. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Country
  • Table 169. Asia Pacific: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Country
  • Table 170. China: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 171. China: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 172. China: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 173. China: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 174. China: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 175. China: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 176. China: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 177. China: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 178. China: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 179. China: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 180. China: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 181. China: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 182. ADULT OBESITY IN 2030
  • Table 183. CHILD OBESITY IN 2030
  • Table 184. Japan: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 185. Japan: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 186. Japan: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 187. Japan: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 188. Japan: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 189. Japan: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 190. Japan: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 191. Japan: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 192. Japan: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 193. Japan: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 194. Japan: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 195. Japan: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 196. India: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 197. India: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 198. India: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 199. India: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 200. India: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 201. India: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 202. India: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 203. India: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 204. India: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 205. India: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 206. India: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 207. India: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 208. Australia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 209. Australia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 210. Australia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 211. Australia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 212. Australia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 213. Australia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 214. Australia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 215. Australia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 216. Australia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 217. Australia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 218. Australia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 219. Australia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 220. South Korea: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 221. South Korea: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 222. South Korea: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 223. South Korea: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 224. South Korea: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 225. South Korea: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 226. South Korea: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 227. South Korea: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 228. South Korea: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 229. South Korea: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 230. South Korea: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 231. South Korea: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 232. Rest of APAC: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 233. Rest of APAC: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 234. Rest of APAC: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 235. Rest of APAC: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 236. Rest of APAC: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 237. Rest of APAC: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 238. Rest of APAC: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 239. Rest of APAC: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 240. Rest of APAC: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 241. Rest of APAC: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 242. Rest of APAC: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 243. Rest of APAC: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 244. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 245. Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 246. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 247. Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 248. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 249. Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 250. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 251. Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 252. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 253. Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 254. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 255. Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 256. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Country
  • Table 257. Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Country
  • Table 258. Saudi Arabia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 259. Saudi Arabia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 260. Saudi Arabia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 261. Saudi Arabia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 262. Saudi Arabia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 263. Saudi Arabia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 264. Saudi Arabia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 265. Saudi Arabia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 266. Saudi Arabia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 267. Saudi Arabia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 268. Saudi Arabia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 269. Saudi Arabia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 270. ADULT OBESITY IN 2030
  • Table 271. CHILD OBESITY IN 2030
  • Table 272. South Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 273. South Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 274. South Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 275. South Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 276. South Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 277. South Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 278. South Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 279. South Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 280. South Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 281. South Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 282. South Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 283. South Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 284. United Arab Emirates: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 285. United Arab Emirates: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 286. United Arab Emirates: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 287. United Arab Emirates: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 288. United Arab Emirates: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 289. United Arab Emirates: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 290. United Arab Emirates: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 291. United Arab Emirates: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 292. United Arab Emirates: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 293. United Arab Emirates: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 294. United Arab Emirates: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 295. United Arab Emirates: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 296. ADULT OBESITY IN 2030
  • Table 297. CHILD OBESITY IN 2030
  • Table 298. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 299. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 300. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 301. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 302. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 303. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 304. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 305. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 306. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 307. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 308. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 309. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 310. South and Central America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 311. South and Central America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 312. South and Central America: Anti-Obesity Drugs Market - Revenue, 20

List Of Figures

  • Figure 1. Anti-Obesity Drugs Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Anti-Obesity Drugs Market Revenue (US$ Million), 2021-2031
  • Figure 5. Anti-Obesity Drugs Market Share (%) - by Type (2024 and 2031)
  • Figure 6. Prescription Drugs: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. OTC Drugs: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Anti-Obesity Drugs Market Share (%) - by Drug Class (2024 and 2031)
  • Figure 9. GLP-1 Agonist: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Lipase Inhibitors: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. MC4R agonist: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Others: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Anti-Obesity Drugs Market Share (%) - by Application (2024 and 2031)
  • Figure 14. Appetite Suppression: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Inhibition of Fat Absorption or Digestive Enzymes: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Metabolic Enhancement: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Combination: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Anti-Obesity Drugs Market Share (%) - by Route Of Administration (2024 and 2031)
  • Figure 19. Oral: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Parenteral: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Anti-Obesity Drugs Market Share (%) - by Distribution Channel (2024 and 2031)
  • Figure 22. Hospital Pharmacies: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Online Channel: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Retail Pharmacies: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Anti-Obesity Drugs Market Breakdown by Region, 2024 and 2031 (%)
  • Figure 26. North America: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 27. North America: Anti-Obesity Drugs Market Breakdown, by Type (2024 and 2031)
  • Figure 28. North America: Anti-Obesity Drugs Market Breakdown, by Drug Class (2024 and 2031)
  • Figure 29. North America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist (2024 and 2031)
  • Figure 30. North America: Anti-Obesity Drugs Market Breakdown, by Application (2024 and 2031)
  • Figure 31. North America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration (2024 and 2031)
  • Figure 32. North America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel (2024 and 2031)
  • Figure 33. North America: Anti-Obesity Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 34. United States: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 35. Canada: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 36. Mexico: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 37. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 38. Europe: Anti-Obesity Drugs Market Breakdown, by Type (2024 and 2031)
  • Figure 39. Europe: Anti-Obesity Drugs Market Breakdown, by Drug Class (2024 and 2031)
  • Figure 40. Europe: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist (2024 and 2031)
  • Figure 41. Europe: Anti-Obesity Drugs Market Breakdown, by Application (2024 and 2031)
  • Figure 42. Europe: Anti-Obesity Drugs Market Breakdown, by Route Of Administration (2024 and 2031)
  • Figure 43. Europe: Anti-Obesity Drugs Market Breakdown, by Distribution Channel (2024 and 2031)
  • Figure 44. Europe: Anti-Obesity Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 45. Germany: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 46. United Kingdom: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 47. France: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 48. Spain: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 49. Italy: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 50. Rest of Europe: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 51. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 52. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Type (2024 and 2031)
  • Figure 53. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Drug Class (2024 and 2031)
  • Figure 54. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist (2024 and 2031)
  • Figure 55. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Application (2024 and 2031)
  • Figure 56. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Route Of Administration (2024 and 2031)
  • Figure 57. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Distribution Channel (2024 and 2031)
  • Figure 58. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 59. China: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 60. Japan: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 61. India: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 62. Australia: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 63. South Korea: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 64. Rest of APAC: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 65. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 66. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Type (2024 and 2031)
  • Figure 67. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class (2024 and 2031)
  • Figure 68. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist (2024 and 2031)
  • Figure 69. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Application (2024 and 2031)
  • Figure 70. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration (2024 and 2031)
  • Figure 71. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel (2024 and 2031)
  • Figure 72. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 73. Saudi Arabia: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 74. South Africa: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 75. United Arab Emirates: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 76. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 77. South and Central America: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 78. South and Central America: Anti-Obesity Drugs Market Breakdown, by Type (2024 and 2031)
  • Figure 79. South and Central America: Anti-Obesity Drugs Market Breakdown, by Drug Class (2024 and 2031)
  • Figure 80. South and Central America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist (2024 and 2031)
  • Figure 81. South and Central America: Anti-Obesity Drugs Market Breakdown, by Application (2024 and 2031)
  • Figure 82. South and Central America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration (2024 and 2031)
  • Figure 83. South and Central America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel (2024 and 2031)
  • Figure 84. South and Central America: Anti-Obesity Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 85. Brazil: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 86. Argentina: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 87. Rest of South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)